Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 3—March 2009
Perspective

Meeting the Challenge of Influenza Pandemic Preparedness in Developing Countries

David S. FedsonComments to Author 
Author affiliation: University of Virginia, Charlottesville, Virginia, USA (retired)

Main Article

Figure

Genetic reassortment and genesis of a new pandemic influenza virus. This study was designed to determine whether the selection and transmission of a new reassortant influenza A virus could occur under experimental conditions in vivo that mimic what might occur in nature. Reassortment between 2 antigenically distinct influenza A viruses was studied in turkeys that had been previously immunized to induce low levels of antibodies to the hemagglutinin (H) of a nonlethal turkey influenza virus (Turke

Figure. Genetic reassortment and genesis of a new pandemic influenza virus. This study was designed to determine whether the selection and transmission of a new reassortant influenza A virus could occur under experimental conditions in vivo that mimic what might occur in nature. Reassortment between 2 antigenically distinct influenza A viruses was studied in turkeys that had been previously immunized to induce low levels of antibodies to the hemagglutinin (H) of a nonlethal turkey influenza virus (Turkey), and to the neuraminidase (N) of a fowl plague virus (FPV), an avian virus that is highly pathogenic for chickens. Twenty-eight days after immunization, the immunized turkeys were sequentially infected, first with the Turkey virus and 4 h later with FPV. During the first few days, both parent viruses were isolated from the infected turkeys, but by day 4 a reassortant virus containing the FPV hemagglutinin and the Turkey neuraminidase (FPV(H)–Turkey(N)) was also isolated; within 2 days it became the dominant virus. All infected turkeys died, and only the FPV(H)–Turkey(N) reassortant virus could be recovered. In a separate experiment, similarly immunized turkeys were again sequentially infected, but on day 5 a group of nonimmunized or selectively immunized turkeys (Turkey(H) FPV(N)) were placed in the same room. All contact birds soon died of fulminant infection caused by the FPV(H)–Turkey(N) reassortant virus. These experiments demonstrated that under conditions of selective primary immunity, a new virus could be generated through genetic reassortment in vivo and that this reassortant virus could be readily transmitted to contacts. The reassortant virus caused uniformly fatal disease in primary infected and contact birds. Thus, under the conditions of these experiments, genetic reassortment gave rise to a new influenza virus that led to a total population collapse. Adapted from Webster and Campbell (9).

Main Article

References
  1. Oshitani  H, Kamigaki  T, Suzuki  A. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis. 2008;14:87580. DOIPubMed
  2. Fedson  DS, Dunnill  P. From scarcity to abundance: pandemic vaccines and other agents for “have not” countries. J Public Health Policy. 2007;28:32240. DOIPubMed
  3. World Health Organization. Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile. WHO scientific consultation. 2007 Oct 1–3; Geneva [cited 2008 Dec 10]. Available from http://www.who.int/csr/resources/publications/WHO_HSE_EPR_GIP_2008_1d.pdf
  4. Higgs  ES, Hayden  FG, Chotpitayasunondh  T, Whitworth  J, Farrar  J. The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. Antiviral Res. 2008;78:648. DOIPubMed
  5. Chen  LM, David  CT, Zhou  H, Cox  NJ, Donis  RO. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog. 2008;4:e1000072. DOIPubMed
  6. Belser  JA, Blixt  O, Chen  LM, Pappas  C, Maines  TR, Van Hoeven  N, Contemporary North America influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. Proc Natl Acad Sci U S A. 2008;105:755863. DOIPubMed
  7. Reports of increased survival in bird flu patients taking Tamiflu. International Symposium on Respiratory Viral Infections; 2008 Mar 2; Singapore [cited 2008 Dec 10]. Available from http://www.antara.co.id/en/print/?i=1204536377
  8. Murray  CJL, Lopez  AD, Chin  B, Feehan  D, Hill  KH. Estimation of potential global influenza mortality on the basis of vital registry data from the 1918–1920 pandemic: a quantitative analysis. Lancet. 2006;368:22118. DOIPubMed
  9. Webster  RG, Campbell  CH. Studies on the origin of pandemic influenza. IV. Selection and transmission of “new” influenza viruses in vivo. Virology. 1974;62:40413. DOIPubMed
  10. Fidler  DP. Influenza virus samples, international law, and global health diplomacy. Emerg Infect Dis. 2008;14:8894. DOIPubMed
  11. Schnirring  L. Indonesia claims wide support for virus-sharing stance. Center for Infectious Disease and Research Policy News. 2008 May 27 [cited 2008 Dec 12]. Available from http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/may2708sharing.html
  12. Fedson  DS. New technologies for meeting the global demand for pandemic influenza vaccines. Biologicals. 2008;36:3469. DOIPubMed
  13. Fedson  DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis. 2006;43:199205. DOIPubMed
  14. Fedson  DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis. 2008;8:5716. DOIPubMed
  15. Butler  D. Cheaper approaches to flu divide flu researchers. Nature. 2007;448:9767. DOIPubMed
  16. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261–73.
  17. van de Garde  EM, Hak  E, Souverein  PC, Hoes  AW, van den Bosch  JM, Leufkens  HG. Statin therapy and reduced risk of pneumonia in patients with diabetes. Thorax. 2006;61:95761. DOIPubMed
  18. Schlienger  RG, Fedson  DS, Jick  S, Jick  H, Meier  C. Statins and the risk of pneumonia: a population-based nested case-control study. Pharmacotherapy. 2007;27:32532. DOIPubMed
  19. Mortensen  EM, Pugh  MJ, Copeland  L, Cornell  J, Restrepo  MI, Anzueto  A, Impact of statins and ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia and influenza. Eur Respir J. 2008;31:6117. DOIPubMed
  20. Chalmers  JD, Singanayagam  A, Murray  MP, Hill  AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med. 2008;121:10027. DOIPubMed
  21. Thomsen  RW, Riis  A, Kornum  JB, Christensen  S, Johnsen  SP, Sorensen  HT. Preadmission use of statins and outcomes after hospitalization with pneumonia. Arch Intern Med. 2008;168:20817. DOIPubMed
  22. Majumdar  SR, McAlister  FA, Eurich  DT, Padwal  RS, Marrie  TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: a population based prospective cohort study. BMJ. 2006;333:9991004. DOIPubMed
  23. Choi  HS, Park  MJ, Kang  HM, Lim  IH, Choi  CW, You  JH. Statin use and mortality in sepsis due to pneumonia. Crit Care Med. 2007;35(Suppl):1362. DOIPubMed
  24. Budd  A, Alleva  L, Alsharifi  M, Koskinen  A, Smytha  V, Mullbacher  A, Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother. 2007;51:29658. DOIPubMed
  25. Palamara  AT, Nencioni  L, Aquilano  K, De Chiara  G, Hernandez  L, Cossolino  F, Inhibition of influenza A virus replication by resveratrol. J Infect Dis. 2005;191:171929. DOIPubMed
  26. Song  JM, Park  KD, Lee  KH, Byun  YH, Park  JH, Kim  SH, Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Res. 2007;76:17885. DOIPubMed
  27. Siddiqui  AM, Cui  X, Wu  R, Dong  W, Zhou  M, Hu  M, The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Crit Care Med. 2006;34:187482. DOIPubMed
  28. Zheng  BJ, Chan  KW, Lin  YP, Zhao  GY, Chan  C, Zhang  HJ, Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A. 2008;105:80916. DOIPubMed
  29. Simmons  C, Farrar  JT. Insights into inflammation. N Engl J Med. 2008;359:16213. DOIPubMed
  30. McAuley  JL, Hornung  F, Boyd  KL, Smith  AM, McKeon  R, Bennick  J, Expression of the 1918 influenza A virus PB1–F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe. 2007;2:2409. DOIPubMed
  31. Imai  Y, Kuba  K, Neely  GG, Yaghubian-Malhami  R, Perkmann  T, van Loo  G, Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133:23549. DOIPubMed
  32. Mizgerd  JP, Skerrett  SJ. Animal models of human lung disease. Am J Physiol Lung Cell Mol Physiol. 2008;294:L38798. DOIPubMed
  33. Fukunaga  K, Kohli  P, Bonnans  C, Fredenburgh  LE, Levy  BD. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol. 2005;174:50339.PubMed
  34. Korteweg  C, Gu  J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol. 2008;172:115570. DOIPubMed
  35. van der Poll  T, Opal  SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:3243. DOIPubMed
  36. Rittirsch  D, Flierl  MA, Ward  PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:77687. DOIPubMed
  37. Carré  JE, Singer  M. Cellular energetic metabolism in sepsis: the need for a systems approach. Biochim Biophys Acta 2008;1777:763–71.
  38. World Health Organization. WHO global conference on severe acute respiratory syndrome (SARS). Where do we go from here? 2003 Jun 17–18 [cited 2008 Dec 10]. Available from http://www.who.int/csr/sars/conference/june_2003/materials/report/en/index.html

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external